Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context

Journal of Breast Cancer ◽

10.4048/jbc.2010.13.3.286 ◽

2010 ◽

Vol 13 (3) ◽

pp. 286 ◽

Author(s):

Hye-Jae Lee ◽

Tae-Jin Lee ◽

Bong-Min Yang ◽

Junwon Min

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Hormonal Treatments

Download Full-text

PCN21 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT HORMONAL TREATMENTS FOR POSTMENOPAUSAL HORMONE-RECEPTOR POSITIVE EARLY BREAST CANCER IN KOREAN CONTEXT

Value in Health ◽

10.1016/s1098-3015(11)73113-8 ◽

2010 ◽

Vol 13 (7) ◽

pp. A513-A514

Author(s):

HJ Lee ◽

TJ Lee ◽

BM Yang

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Hormonal Treatments

Download Full-text

PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK

Value in Health ◽

10.1016/s1098-3015(10)67270-1 ◽

2005 ◽

Vol 8 (6) ◽

pp. A43

Author(s):

J Karnon ◽

TE Delea ◽

NL Papo ◽

V Barghout ◽

SK Thomas ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Therapy ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Download Full-text

P181 Cost-effectiveness analysis of letrozole vs. tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the Belgian perspective

10.1016/s0960-9776(07)70241-2 ◽

2007 ◽

Vol 16 ◽

pp. S64-S65

Author(s):

J. Karnon ◽

M. Berli`ere ◽

H. Depypere ◽

L. Dirix ◽

G. Jerusalem ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Therapy ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3107-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 443-443 ◽

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK

PharmacoEconomics - Open ◽

10.1007/s41669-019-0134-3 ◽

2019 ◽

Vol 3 (4) ◽

pp. 559-570 ◽

Author(s):

Claire Telford ◽

Evelina Bertranou ◽

Samuel Large ◽

Hilary Phelps ◽

Mattias Ekman ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Download Full-text

Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-019-05190-3 ◽

2019 ◽

Vol 175 (3) ◽

pp. 775-779 ◽

Author(s):

Bingnan Zhang ◽

Elisa F. Long

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer

European Journal of Cancer Care ◽

10.1111/ecc.12733 ◽

2017 ◽

Vol 26 (6) ◽

pp. e12733 ◽

Author(s):

H. Ding ◽

L. Fang ◽

W. Xin ◽

Y. Tong ◽

Q. Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as frist-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): A UK perspective

European Journal of Cancer ◽

10.1016/s0959-8049(02)80202-7 ◽

2002 ◽

Vol 38 (11) ◽

pp. S68

Author(s):

R Simons

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Download Full-text

Cost Effectiveness Analysis of Exemestane Versus Capecitabine Monotherapy for Patients with Hormone Receptor–Positive and Her2-Negative, Metastatic Breast Cancer from National Cancer Institute Prespective in Egypt

Value in Health ◽

10.1016/j.jval.2017.08.207 ◽

2017 ◽

Vol 20 (9) ◽

pp. A434

Author(s):

H Abdallah ◽

AS Abourawash ◽

M Elgazzar ◽

A Helal

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

National Cancer Institute ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text